Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial. (PubMed, J Immunother Precis Oncol) - Feb 17, 2025 - P1 | "The combination of lefitolimod (administered subcutaneously or intratumorally) and ipilimumab was safe and well tolerated but demonstrated modest antitumor activity in patients with advanced cancers. ClinicalTrials.gov ID: NCT02668770."
Journal • P1 data • Dermatology • Fatigue • Oncology • Pruritus • Solid Tumor • CD8
|
|
Amadeo B Biter; Apostolia M Tsimberidou; Aung Naing; Casey R Ager; Coline A Couillault; Daniel D Karp; David S Hong; JoAnn Lim; Jordi Rodon; Ly M Nguyen; Matthew J Reilley; Michael A Curran; Mirella Nardo; Mohamed A Gouda; Priya R Bhosale; Sarina A Piha-Paul; Siqing Fu; Stacie A Bean; Timothy A Yap; Vivek Subbiah
|